A Novel Method for Breast Cancer Prognosis

AviaraDx reported that a study conducted in collaboration with Baylor College of Medicine further demonstrated the clinical utility of two novel genes for the identification of patients at higher risks of early breast cancer recurrence. This study has been published in the October issue of “Journal of Clinical Oncology.”

The 852-patient retrospective study confirms the original discovery of the two-gene ratio of HOXB13/ IL17BR (H/I) as an independent prognostic marker for risk of recurrence in tamoxifen-treated, estrogen receptor-positive (ER+) and lymph node-negative patients. The study also extend the prognostic utility of the H/I ratio to untreated patients.

According to AviaraDx CEO Antonius Schuh, the study was the third in a series of clinical studies conducted to validate the clinical utility of the H/I ratio as a very significant prognostic biomarker in ER+ breast cancer patients.

AviaraDx discovered both biomarkers in a collaborative study with Harvard Medical School and Massachusetts General Hospital, which was published in the June 2004 issue of “Cancer Cell.” In April 2006, a collaborative study with Mayo Clinic, showing significant clinical utility of H/I in patients treated with tamoxifen, was published in the journal “Clinical Cancer Research.”

Source: genengnews.com/news/bnitem.aspx?name=6864190